Press

Psyched Wellness’s Calm, First Legal Amanita Muscaria Extract, Arrives at Pop-up Grocer in NYC

Dec 12 • 2 min read

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is thrilled to announce its debut at Pop-up Grocer, the revered hub for innovative and groundbreaking products. Starting December 15th, consumers in…

Filament Health Announces Adjournment of Special Meeting

Dec 12 • 3 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. (Vancouver time) (the “Special Meeting“) to approve, among other things, the Company’s proposed arrangement (the “Arrangement“) under Part 9, Division 5 of the Business…

Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities

Dec 11 • 3 min read

Beckley Retreats, a psilocybin retreats and holistic wellbeing company, announced today the launch of the Beckley Retreats Scholarship Program beginning now and through 2024, which aims to foster diversity and expand access to psychedelic experiences for those who may not otherwise be able to participate. In 2024, Beckley Retreats will offer dedicated retreats in Jamaica…

Red Light Holland’s GMP Manufactured Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Five Month Stability Testing by CCrest Laboratories in Montreal, Canada

Dec 11 • 4 min read

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance…

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited

Dec 11 • 10 min read

Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the Company has entered into an arrangement agreement (the “Arrangement Agreement“) with Exopharm Limited ACN 163 765 991 (“Exopharm” or the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435